Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$88.90 USD
+0.52 (0.59%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $88.94 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Company Summary
Cambridge, MA-based Blueprint Medicines Corporation is a biopharmaceutical company, focused on developing potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
Blueprint Medicines lead drug Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, was approved by the Food and Drug Administration (FDA) to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) in January 2020. The drug was approved in Europe in September 2020. In 2023, Ayvakit generated sales worth $204.2 million, up 84% year over year. In June 2021, the FDA approved Ayvakit for treating advanced SM. In May 2023, the FDA expanded Ayvakit’...
Company Summary
Cambridge, MA-based Blueprint Medicines Corporation is a biopharmaceutical company, focused on developing potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
Blueprint Medicines lead drug Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, was approved by the Food and Drug Administration (FDA) to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) in January 2020. The drug was approved in Europe in September 2020. In 2023, Ayvakit generated sales worth $204.2 million, up 84% year over year. In June 2021, the FDA approved Ayvakit for treating advanced SM. In May 2023, the FDA expanded Ayvakit’s label to include the treatment of indolent SM in adults. The drug is also approved in Europe for advanced and indolent SM.
Gavreto (pralsetinib) is approved for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The drug is also approved for RET-mutant and RET fusion-positive thyroid cancer. Blueprint Medicines was co-developing Gavreto with Roche. However, following Roche’s decision to discontinue the collaboration agreement, Blueprint is set to regain the global commercial rights to Gavreto in late February.
Fisogatinib is being evaluated in the phase I program for administering it to patients with hepatocellular carcinoma (HCC). Meanwhile, eenestinib (BLU-263) is currently being developed for treating indolent SM (in a phase II/III HARBOR study) and other mast cell disorders. Blueprint Medicines has a collaboration agreement with CStone Pharmaceuticals for the development and commercialization of three clinical-stage candidates in Mainland China, Hong Kong, Macau, and Taiwan.
Blueprint Medicines currently draws revenues from Ayvakit sales and collaboration revenues primarily generated from the agreements with CStone and Roche.
Blueprint also nominated BLU-808, an oral KIT inhibitor as a development candidate for the treatment of mast cell disorders, including chronic urticaria.
For 2023, Blueprint Medicines generated total revenues of $249.4 million compared with $204 million recorded in 2022.
General Information
Blueprint Medicines Corporation
45 SIDNEY STREET
CAMBRIDGE, MA 02139
Phone: 617-374-7580
Fax: NA
Web: http://www.blueprintmedicines.com
Email: ir@blueprintmedicines.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/2/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.65 |
Current Year EPS Consensus Estimate | -5.42 |
Estimated Long-Term EPS Growth Rate | 34.00 |
Exp Earnings Date | 5/2/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 88.38 |
52 Week High | 101.00 |
52 Week Low | 43.89 |
Beta | 0.63 |
20 Day Moving Average | 560,656.06 |
Target Price Consensus | 94.40 |
4 Week | 0.14 |
12 Week | 7.94 |
YTD | -4.18 |
4 Week | 4.17 |
12 Week | 4.64 |
YTD | -9.00 |
Shares Outstanding (millions) | 61.20 |
Market Capitalization (millions) | 5,408.86 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 31.32% |
vs. Previous Quarter | 17.27% |
vs. Previous Year | 85.55% |
vs. Previous Quarter | 27.21% |
Price/Book | 41.13 |
Price/Cash Flow | NA |
Price / Sales | 21.69 |
3/31/24 | NA |
12/31/23 | -191.56 |
9/30/23 | -153.79 |
3/31/24 | NA |
12/31/23 | -45.25 |
9/30/23 | -46.40 |
3/31/24 | NA |
12/31/23 | 3.76 |
9/30/23 | 4.09 |
3/31/24 | NA |
12/31/23 | 3.66 |
9/30/23 | 4.01 |
3/31/24 | NA |
12/31/23 | -203.30 |
9/30/23 | -256.57 |
3/31/24 | NA |
12/31/23 | -203.30 |
9/30/23 | -256.57 |
3/31/24 | NA |
12/31/23 | -202.91 |
9/30/23 | -255.67 |
3/31/24 | NA |
12/31/23 | 2.15 |
9/30/23 | 3.33 |
3/31/24 | NA |
12/31/23 | 0.71 |
9/30/23 | 0.96 |
3/31/24 | NA |
12/31/23 | 1.60 |
9/30/23 | 1.03 |
3/31/24 | NA |
12/31/23 | 61.49 |
9/30/23 | 50.67 |